2015
DOI: 10.1186/s12920-015-0111-3
|View full text |Cite
|
Sign up to set email alerts
|

Using gene expression signatures to identify novel treatment strategies in gulf war illness

Abstract: BackgroundGulf War Illness (GWI) is a complex multi-symptom disorder that affects up to one in three veterans of this 1991 conflict and for which no effective treatment has been found. Discovering novel treatment strategies for such a complex chronic illness is extremely expensive, carries a high probability of failure and a lengthy cycle time. Repurposing Food and Drug Administration approved drugs offers a cost-effective solution with a significantly abbreviated timeline.MethodsHere, we explore drug re-purpo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
14
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
2
1

Relationship

2
7

Authors

Journals

citations
Cited by 24 publications
(16 citation statements)
references
References 83 publications
(112 reference statements)
1
14
0
Order By: Relevance
“…Regulation of glucocorticoid responsiveness is complex however there is evidence that the latter is also reduced by exposure to proinflammatory cytokines, such as tumor necrosis factor a (TNFa) and interleukin-1b (IL-1b), 18 both of which are suggested to play a role in GWI. 4,19 Among its broad-reaching effects GR interacts with receptor tyrosine kinase to promote BDNFinduced release of glutamate. SiRNA transfection inducing a decrease in endogenous GR has been shown to decrease BDNFdependent binding of phospholipase C-g (PLC-g) to tyrosine kinase B (TrkB) resulting in the suppression of neurotransmitter release.…”
Section: Discussionmentioning
confidence: 99%
“…Regulation of glucocorticoid responsiveness is complex however there is evidence that the latter is also reduced by exposure to proinflammatory cytokines, such as tumor necrosis factor a (TNFa) and interleukin-1b (IL-1b), 18 both of which are suggested to play a role in GWI. 4,19 Among its broad-reaching effects GR interacts with receptor tyrosine kinase to promote BDNFinduced release of glutamate. SiRNA transfection inducing a decrease in endogenous GR has been shown to decrease BDNFdependent binding of phospholipase C-g (PLC-g) to tyrosine kinase B (TrkB) resulting in the suppression of neurotransmitter release.…”
Section: Discussionmentioning
confidence: 99%
“…Now, there is a link between chronic infections and the development of autoimmune disorders (Sherbet, 2009). In addition, a possible, direct connection of GWI to autoimmunity has been suggested (Asa et al, 2000, Israeli, 2012, Georgopoulos et al, 2015) and supported by the emergence of methotrexate, an immunosuppressive drug, as a possible treatment for GWI (Craddock et al, 2015). …”
Section: Discussionmentioning
confidence: 99%
“…Vaccinations obviously target the immune system by inducing immune responses to the pathogens, but also to the adjuvants, contained in the vaccines (Israeli, 2012, Toubi, 2012); chemical exposure to subclinical levels of sarin have been shown to depress immune function (Henderson et al, 2001); and stress has since long been identified as affecting immune function (see reviews by O'Leary, 1990, Webster Marketona and Glasera, 2008). Recent studies have documented immune dysfunction in GWI (Whistler et al, 2009), and even identified an immunosuppressant (methotrexate) as an optimal possible treatment for GWI (Craddock et al, 2015). …”
Section: Introductionmentioning
confidence: 99%
“…This study was designed to build on this research and investigate these markers and biological systems using a methodology to identify genomic modules and their applications in potential secondary pharmacologic actions. 12 In addition, this study was formulated to investigate the differentiation of ME/CFS via gender and to investigate gene-expression covariance with fatigue measures in ME/CFS. Therefore, this study used biological variables to pinpoint potential treatment targets, as treatment options for ME/CFS are currently limited, as well as preliminary diagnostic markers through biomarker and measures of fatigue.…”
Section: Introductionmentioning
confidence: 99%